← boothcheck

Is STE overvalued?

boothcheck doesn't label STE overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, STE is priced for growth of +17.1%, and an operating margin near 7.4% versus the 18.0% it earns today. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The more the price assumes beyond what STERIS plc has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from STERIS plc's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 11, 2026.

Implied growth+17.1%
For about
Margin needed7.4%
Margin today18.0%
Price vs asset value2.34x
Price vs earnings power2.54x
Price vs peer multiples0.96x
Price vs forward growth0.89x
Read the full STE report →
Get boothcheck's read on what STE's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.